Varicella zoster virus in inflammatory bowel disease patients: what every gastroenterologist should know.


Journal

Journal of Crohn's & colitis
ISSN: 1876-4479
Titre abrégé: J Crohns Colitis
Pays: England
ID NLM: 101318676

Informations de publication

Date de publication:
27 Jun 2020
Historique:
received: 30 03 2020
entrez: 28 6 2020
pubmed: 28 6 2020
medline: 28 6 2020
Statut: aheadofprint

Résumé

Primary Varicella Zoster virus (VZV) infection results in varicella (chickenpox) while its reactivation results in herpes zoster (HZ; shingles). Patients with Inflammatory Bowel Disease (IBD) are susceptible to complications of primary VZV infection and have an increased risk of HZ. Concerns of VZV and HZ infection in the IBD population has been highlighted by the emergence of JAK-inhibitors and their safety profile in this patient population such as tofacitinib for the treatment of ulcerative colitis (UC). The current pipeline of emerging therapies include novel molecules targeting multiple pathways including JAK/signal transducer and cytokine signalling pathways such as JAK/STAT. Hence VZV and HZ will be increasingly relevant for gastroenterologists treating IBD patients in light of these emerging therapies.

Identifiants

pubmed: 32592587
pii: 5864104
doi: 10.1093/ecco-jcc/jjaa132
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of European Crohn's and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Philipp Schreiner (P)

Department of Gastroenterology & Hepatology, University Hospital Zurich.

Nicolas J Mueller (NJ)

Department of Infectious Diseases & Hospital Epidemiology, University Hospital Zurich, Switzerland.

Jan Fehr (J)

Department of Infectious Diseases & Hospital Epidemiology, University Hospital Zurich, Switzerland.
Department of Public & Global Health, University of Zurich, Zurich, Switzerland.

Michel H Maillard (MH)

Crohn and Colitis Center, Gastroentérologie Beaulieu SA, Lausanne, Switzerland.
Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.

Stephan Brand (S)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kantonsspital Sankt Gallen, St. Gallen, Switzerland.

Pierre Michetti (P)

Crohn and Colitis Center, Gastroentérologie Beaulieu SA, Lausanne, Switzerland.
Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.

Alain Schoepfer (A)

Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.

Sophie Restellini (S)

Department of Gastroenterology and Hepatology, Geneva University Hospitals and University of Geneva, Switzerland.

Marianne Vulliemoz (M)

Crohn and Colitis Center, Gastroentérologie Beaulieu SA, Lausanne, Switzerland.

Stephan R Vavricka (SR)

Department of Gastroenterology & Hepatology, University Hospital Zurich.
Center of Gastroenterology and Hepatology, CH, Zurich, Switzerland.

Pascal Juillerat (P)

Gastroenterology, Clinic for Visceral Surgery and Medicine, Inselspital, University Hospital of Bern, Bern, Switzerland.

Gerhard Rogler (G)

Department of Gastroenterology & Hepatology, University Hospital Zurich.

Classifications MeSH